JP2008501649A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501649A5
JP2008501649A5 JP2007513783A JP2007513783A JP2008501649A5 JP 2008501649 A5 JP2008501649 A5 JP 2008501649A5 JP 2007513783 A JP2007513783 A JP 2007513783A JP 2007513783 A JP2007513783 A JP 2007513783A JP 2008501649 A5 JP2008501649 A5 JP 2008501649A5
Authority
JP
Japan
Prior art keywords
group
compound
formula
lower alkyl
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513783A
Other languages
English (en)
Japanese (ja)
Other versions
JP4594386B2 (ja
JP2008501649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/005594 external-priority patent/WO2005117865A1/en
Publication of JP2008501649A publication Critical patent/JP2008501649A/ja
Publication of JP2008501649A5 publication Critical patent/JP2008501649A5/ja
Application granted granted Critical
Publication of JP4594386B2 publication Critical patent/JP4594386B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007513783A 2004-06-02 2005-05-24 ヒスタミン3受容体のリガンドとして有用なナフタレン誘導体 Expired - Fee Related JP4594386B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102460 2004-06-02
PCT/EP2005/005594 WO2005117865A1 (en) 2004-06-02 2005-05-24 Naphthaline derivatives useful as histamine-3-receptor ligands

Publications (3)

Publication Number Publication Date
JP2008501649A JP2008501649A (ja) 2008-01-24
JP2008501649A5 true JP2008501649A5 (https=) 2010-09-24
JP4594386B2 JP4594386B2 (ja) 2010-12-08

Family

ID=34982058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513783A Expired - Fee Related JP4594386B2 (ja) 2004-06-02 2005-05-24 ヒスタミン3受容体のリガンドとして有用なナフタレン誘導体

Country Status (24)

Country Link
US (2) US7259158B2 (https=)
EP (1) EP1755593B1 (https=)
JP (1) JP4594386B2 (https=)
KR (1) KR100854212B1 (https=)
CN (1) CN1960727B (https=)
AR (1) AR049433A1 (https=)
AT (1) ATE383857T1 (https=)
AU (1) AU2005249196B2 (https=)
BR (1) BRPI0511778A (https=)
CA (1) CA2566526C (https=)
DE (1) DE602005004404T2 (https=)
DK (1) DK1755593T3 (https=)
ES (1) ES2299074T3 (https=)
IL (1) IL179370A (https=)
MX (1) MXPA06014017A (https=)
MY (1) MY139704A (https=)
NO (1) NO20065733L (https=)
NZ (1) NZ550764A (https=)
PL (1) PL1755593T3 (https=)
PT (1) PT1755593E (https=)
RU (1) RU2387638C2 (https=)
TW (1) TWI299992B (https=)
WO (1) WO2005117865A1 (https=)
ZA (1) ZA200609678B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988143A4 (en) 2006-02-20 2009-11-25 Konica Minolta Holdings Inc ORGANIC ELECTROLUMINESCENT ELEMENT, WHITE LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
EP2152669A1 (en) 2007-05-03 2010-02-17 Cephalon, Inc. Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof
BRPI0820171B8 (pt) 2007-11-16 2021-05-25 Rigel Pharmaceuticals Inc compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
CA2707047C (en) 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
MX2010011288A (es) 2008-04-23 2010-11-09 Rigel Pharmaceuticals Inc Compuestos de carboxamida para el tratamiento de trastornos metabolicos.
AR083718A1 (es) 2010-05-11 2013-03-20 Sanofi Aventis Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas
WO2011143162A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
EP2569297A1 (en) 2010-05-11 2013-03-20 Sanofi Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
WO2011143155A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換n−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
TW201206889A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
KR101408699B1 (ko) 2012-02-29 2014-06-19 중앙대학교 산학협력단 지르코늄 선택적 형광 프루브
EA027809B1 (ru) * 2012-07-27 2017-09-29 Биоген Айдек Ма Инк. Соединения, которые являются s1p-модулирующими агентами и/или atx-модулирующими агентами
US9555050B2 (en) 2012-07-27 2017-01-31 Biogen Ma Inc. ATX modulating agents
CA2878217C (en) * 2012-08-23 2016-05-17 Suven Life Sciences Limited Acrylamide compounds as histamine h3 receptor ligands
CN117229207B (zh) * 2023-09-01 2024-09-03 浙江工业大学 一种苯基萘类化合物及其制备与应用
CN121494783A (zh) * 2026-01-13 2026-02-10 安徽农业大学 四氢异喹啉酰胺衍生物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19621483A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
SI0923542T1 (en) * 1996-05-31 2004-02-29 Pharmacia & Upjohn Company Aryl substituted cyclic amines as selective dopamine d3 ligands
JP2004532834A (ja) * 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンh3受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
JP4820094B2 (ja) * 2002-11-12 2011-11-24 アボット・ラボラトリーズ ヒスタミン−3受容体リガンドとしての2環式置換アミン
MX2007004465A (es) * 2004-10-19 2007-05-07 Hoffmann La Roche Derivados de quinolina.

Similar Documents

Publication Publication Date Title
JP2008501649A5 (https=)
RU2011129383A (ru) Производное амина, обладающее антагостической активностью в отношении рецептора npy y5
WO2008006043A3 (en) 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
JP2005527336A5 (https=)
JP2005514410A5 (https=)
JP2005523310A5 (https=)
JP2009541415A5 (https=)
JP2009541403A5 (https=)
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
JP2010520851A5 (https=)
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
JP2008519084A5 (https=)
JP2004535380A5 (https=)
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
JP2006522692A5 (https=)
TW200745039A (en) Isotopically substituted pantoprazole
JP2001354766A5 (https=)
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments
HRP20110780T1 (hr) Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6
JP2003504349A5 (https=)
DE602006001330D1 (de) Herstellung von 1-(Alkoxysilyl)ethyl-1,1,3,3-tetramethyldisiloxan
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
DE602004030779D1 (de) Angehen des problems des schrittmachersyndroms
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
JP2006206765A5 (https=)